top of page

The world isn’t flat. Despite major breakthroughs in the sequencing world, Next Generation Sequencing is stuck to their traditional flat structure. But is flat the best way to unleash top performance?

Adding a new dimension to DNA Sequencing

Single Technologies thinks otherwise and has created 3-D Sequencing™ – a cube style sequencing solution that taps a new level of performance and goes beyond traditional scaling. As a multi-story infrastructure that moves us from flat surface to three-dimensional cube, 3-D Sequencing™ drastically increase the number of DNA sequences that can be read in parallel and naturally unite sequencing with spatial biology.

“Our vision is removing the bottleneck of generating sequencing data allowing scientists, empowered with AI, to solve complex biological problems.”

JOHAN STRÖMQVIST – FOUNDER/CEO
APPLICATIONS

Why is exponentially more genomics data needed?

The demand for sequencing data is growing exponentially due to increased usage of AI within life sciences, the evolving role of sequencing in screening and diagnosis for multiple diseases and the increased usage of synthetic DNA tags in many new verticals.

DISCOVERY

Large-scale database generation

Several fields within the life science industry are now transitioning to sequencing methods. For example in proteomics Olink has developed a technology utilizing synthetic DNA tags on antibodies and sequencing to measure the concentration of 5000 different proteins in a single drop of blood. Samples of 53,000 individuals have been analyzed in the UK Biobank Pharma Proteomics Project, helping scientists better understand how and why diseases develop and drive the development of new diagnostics and treatments.

DIAGNOSIS

Screening with AI for early detection

Screening populations using cell free DNA in the blood is already established for prenatal testing with NIPT, offering high accuracy without the risk of miscarriage. The next area is early cancer detection where kits are becoming available, for example Grail’s Galleri which tests for 50 types of cancer with a single blood test. The test was developed using massive sequencing data to train a deep learning algorithm, showcasing the importance of combining sequencing with AI to develop new diagnostics.

TREATMENT

Gene editing and reprogramming cells

REGENERAR is a consortium including Coimbra university and Helmholtz Zentrum to promote brain repair. The project’s aim is to use CRISPR to reprogram healthy glial cells into neurons, thereby potentially cure stroke patients where neurons are irreversible damaged. DNA-tags are used to identify that the correct genes are activated in the reprogrammed cells. 3-D Sequencing™ is an important tool in the progress of identifying novel therapeutic approaches.

MEET OUR ADVISORS

Bob Kain

Former Chief Engineering Officer Illumina and a renowned pioneer in genomics. Bob led the invention of the modern, high throughput genome sequencer that brought the cost from millions of dollars down to less than $1000 and led to Illumina’s success and domination of the NGS field. Bob is lead inventor on 28 U.S. patents that led to the breakthroughs that have revolutionized genome sequencing.

Ulf Landegren

MD and PhD, professor of molecular medicine at Uppsala and previously postdoc with Lee Hood at Caltech. Ulf has authored 230 peer-reviewed publications, and he is inventor of 50 patents or applications. His unique innovations include padlock probes for measuring DNA and proximity ligation assays for detecting proteins. Ten biotech companies have their origins from Ulf including Olink and ParAllele Biosciences. Member of EMBO and the Royal Swedish Academy of Sciences.

The Power of Theta

THE WORLD’S FIRST 3-D SEQUENCER

Next Generation Sequencing will after the introduction of the patented Theta no more be limited to surfaces and channels but instead analyze by volume rather than area, increasing the potential number of reads in a run many times and at much lower cost.

Matrix

Our unique 3-D matrix enables massively parallel reactions in three dimensions, allowing DNA to be distributed efficiently in a volume, increasing bandwidth and lowering cost. Our matrix also has the unique ability to contain cells and tissue, opening doors to spatial genomics.

Theta 3-D Sequencer

Theta is a fully automatic sequencer imaging in 3-D with single molecule sensitivity at the optical resolution limit, currently 800 times faster than a confocal microscope, and effectively using and rapidly exchanging SBS reagents within the matrix utilizing proprietary 3-D fluidics.

Server

The image data is transferred to a server solution where unique 3-D base calling algorithms and machine learning identify the correct bases and align reads. The generated sequencing data is stored as a standardized FASTQ file.

What is 3-D Sequencing?

UNDER THE HOOD

True confocal scanner

Single’s system is the world’s fastest true confocal scanner, imaging large areas in three dimensions at the optical resolution limit with single fluorescence molecule sensitivity.

Open fluidics

Single’s unique open fluidics exchange liquids and reagents in three dimensions, allowing rapid distribution of liquids over large volumes and efficiently using valuable reagents.

Volumetric amplification

Single’s platform performs massively parallel reactions in three dimensions, enabling the detection of sequences at all sites in a volume independent of sample or molecule.

Matrix

<xdasdfasdasd

APPLICATIONS

Why is exponentially more genomics data needed?

The demand for sequencing data is growing exponentially due to increased usage of AI within life sciences, the evolving role of sequencing in screening and diagnosis for multiple diseases and the increased usage of synthetic DNA tags in many new verticals.

DISCOVERY

Large-scale datasets generation

Our unique 3-D matrix enables massively parallel reactions in three dimensions, allowing DNA to be distributed efficiently in a volume, increasing bandwidth and lowering cost. Our matrix also has the unique ability to contain cells and tissue, opening doors to spatial genomics.

DIAGNOSIS

Screening for early detection

Screening populations using cell free DNA in the blood is already established for prenatal testing with NIPT, offering high accuracy without the risk of miscarriage. The next area is early cancer detection where kits are becoming available, for example Grail’s Galleri which tests for 50 types of cancer with a single blood test. The test was developed using massive sequencing data to train a deep learning algorithm, showcasing the importance of combining sequencing with AI to develop new diagnostics.

TREATMENT

Gene editing and reprogramming cells

REGENERAR is a consortium including Coimbra university and Helmholtz Zentrum to promote brain repair. The project’s aim is to use CRISPR to reprogram healthy glial cells into neurons, thereby potentially cure stroke patients where neurons are irreversible damaged. DNA-tags are used to identify that the correct genes are activated in the reprogrammed cells. 3-D Sequencing™ is an important tool in the progress of identifying novel therapeutic approaches.

SUPPORTED BY

Former Chief Engineering Officer Illumina and a renowned pioneer in genomics. Bob led the invention of the modern, high throughput genome sequencer that brought the cost from millions of dollars down to less than $1000 and led to Illumina’s success and domination of the NGS field. Bob is lead inventor on 28 U.S. patents that led to the breakthroughs that have revolutionized genome sequencing.

Bob Kain

MD and PhD, professor of molecular medicine at Uppsala and previously postdoc with Lee Hood at Caltech. Ulf has authored 230 peer-reviewed publications, and he is inventor of 50 patents or applications. His unique innovations include padlock probes for measuring DNA and proximity ligation assays for detecting proteins. Ten biotech companies have their origins from Ulf including Olink and ParAllele Biosciences. Member of EMBO and the Royal Swedish Academy of Sciences.

Ulf Landegren

Gene editing and reprogramming cells

SUPPORTED BY

Single Technologies begs to differ, Introducing 3-D Sequencing™ – a cube style sequencing solution that taps a new level of performance and goes beyond traditional scaling. As a multi-story infrastructure that transcends conventional limitations to embrace a three-dimensional cube framework.

 

3-D Sequencing™ significantly amplifies parallel sequencing capabilities, enabling a substantial increase in the number of DNA sequences read concurrently while integrating sequencing with spatial biology.

Single Technologies AB
Sankt Eriksgatan 48F
112 34 Stockholm
Sweden

sales@singletechnologies.com

+46 (0) 735 280 550

Socials

© 2024 Single Technologies AB. All rights reserved.

APPLICATIONS

Why is exponentially more genomics data needed?

The demand for sequencing data is growing exponentially due to increased usage of AI within life sciences, the evolving role of sequencing in screening and diagnosis for multiple diseases and the increased usage of synthetic DNA tags in many new verticals.

DISCOVERY

Large-scale datasets generation

Our unique 3-D matrix enables massively parallel reactions in three dimensions, allowing DNA to be distributed efficiently in a volume, increasing bandwidth and lowering cost. Our matrix also has the unique ability to contain cells and tissue, opening doors to spatial genomics.

DIAGNOSIS

Screening for early detection

Screening populations using cell free DNA in the blood is already established for prenatal testing with NIPT, offering high accuracy without the risk of miscarriage. The next area is early cancer detection where kits are becoming available, for example Grail’s Galleri which tests for 50 types of cancer with a single blood test. The test was developed using massive sequencing data to train a deep learning algorithm, showcasing the importance of combining sequencing with AI to develop new diagnostics.

TREATMENT

Gene editing and reprogramming cells

REGENERAR is a consortium including Coimbra university and Helmholtz Zentrum to promote brain repair. The project’s aim is to use CRISPR to reprogram healthy glial cells into neurons, thereby potentially cure stroke patients where neurons are irreversible damaged. DNA-tags are used to identify that the correct genes are activated in the reprogrammed cells. 3-D Sequencing™ is an important tool in the progress of identifying novel therapeutic approaches.

APPLICATIONS

Why is exponentially more genomics data needed?

Several fields within the life science industry are now transitioning to sequencing methods. For example in proteomics Olink has developed a technology utilizing synthetic DNA tags on antibodies and sequencing to measure the concentration of 5000 different proteins in a single drop of blood. Samples of 53,000 individuals have been analyzed in the UK Biobank Pharma Proteomics Project, helping scientists better understand how and why diseases develop and drive the development of new diagnostics and treatments.

APPLICATIONS

Why is exponentially more genomics data needed?

The demand for sequencing data is growing exponentially due to increased usage of AI within life sciences, the evolving role of sequencing in screening and diagnosis for multiple diseases and the increased usage of synthetic DNA tags in many new verticals.

TREATMENT

Gene editing and reprogramming cells

REGENERAR is a consortium including Coimbra university and Helmholtz Zentrum to promote brain repair. The project’s aim is to use CRISPR to reprogram healthy glial cells into neurons, thereby potentially cure stroke patients where neurons are irreversible damaged. DNA-tags are used to identify that the correct genes are activated in the reprogrammed cells. 3-D Sequencing™ is an important tool in the progress of identifying novel therapeutic approaches.

DISCOVERY

Large-scale datasets generation

Several fields within the life science industry are now transitioning to sequencing methods. For example in proteomics Olink has developed a technology utilizing synthetic DNA tags on antibodies and sequencing to measure the concentration of 5000 different proteins in a single drop of blood. Samples of 53,000 individuals have been analyzed in the UK Biobank Pharma Proteomics Project, helping scientists better understand how and why diseases develop and drive the development of new diagnostics and treatments.

Singapore Biobank

Project

Regenerar

consortium 

DIAGNOSIS

Screening for early detection

Screening populations using cell free DNA in the blood is already established for prenatal testing with NIPT, offering high accuracy without the risk of miscarriage. The next area is early cancer detection where kits are becoming available, for example Grail’s Galleri which tests for 50 types of cancer with a single blood test. The test was developed using massive sequencing data to train a deep learning algorithm, showcasing the importance of combining sequencing with AI to develop new diagnostics.

The power of Theta

THE WORLD’S FIRST 3-D SEQUENCER 2

The demand for sequencing data is growing exponentially due to increased usage of AI within life sciences, the evolving role of sequencing in screening and diagnosis for multiple diseases and the increased usage of synthetic DNA tags in many new verticals.

Matrix

Our unique 3-D matrix enables massively parallel reactions in three dimensions, allowing DNA to be distributed efficiently in a volume, increasing bandwidth and lowering cost. Our matrix also has the unique ability to contain cells and tissue, opening doors to spatial genomics.

Theta 3-D Sequencer

Theta is a fully automatic sequencer imaging in 3-D with single molecule sensitivity at the optical resolution limit, currently 800 times faster than a confocal microscope, and effectively using and rapidly exchanging SBS reagents within the matrix utilizing proprietary 3-D fluidics.

Server

The image data is transferred to a server solution where unique 3-D base calling algorithms and machine learning identify the correct bases and align reads. The generated sequencing data is stored as a standardized FASTQ file.

SUPPORTED BY